Neurogene Inc. Common Stock (NGNE)
Stock · NASDAQ · Health Care
$23.28as of 10/16/2026
Price chart
Active signals
NGNE Signal Track Record
How signals performed across all stocks →What NGNE's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | +9.1% | 71% | September 18, 2026 |
| Bollinger Band Breakout | 26 | +4.5% | 58% | August 19, 2026 |
| Bollinger Band Breakdown | 16 | -4.1% | 38% | September 15, 2026 |
| 200-Day Moving Average TouchActive now | 14 | -4.4% | 43% | April 9, 2026 |
| Any 20-session window (baseline) | +0.9% | 51% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About NGNE
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 131
- Website
- www.neurogene.com/
Fundamentals
- 1-day range
- $22.35$24.4
- Market cap
- $680.52M
- P/E (trailing)
- —
- P/E (forward)
- -4.18
- EPS (trailing)
- $-3.16
- Dividend yield
- —
- Beta
- 1.71
- Avg. volume
- 267.2K
How Neurogene Inc. Common Stock Makes Money
Where the revenue actually goes — FY2024 annual results
Source: 10-K filed Mar 24, 2025 · via SEC EDGAR / Finnhub
Forecasts
8 analyst ratings
Neurogene Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- NGNENeurogene Inc. Common Stock$23.25▼ 2.92%Market cap $680.52MP/E —$15.93$43.66
- PHATPhathom Pharmaceuticals Inc. Common Stock$6.92▼ 7.73%Market cap $678.76MP/E —$6.52$18.31
- HELPCybin Inc. Common Stock$10.55▼ 4.52%Market cap $688.02MP/E —$5.3$20.88
- EVOEvotec SE American Depositary Shares$1.38▼ 2.82%Market cap $693.72MP/E —$2.41$7.3
- FBIOPFortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock$16.67▼ 1.30%Market cap $662.39MP/E 0.58$1.88$4.53
- IRWDIronwood Pharmaceuticals Inc. Class A Common Stock$3.5▼ 7.16%Market cap $701.25MP/E 4.68$1.41$5.78
- IMMXImmix Biopharma Inc. Common Stock$7.98▼ 8.06%Market cap $702.09MP/E —$2.31$15.1
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| NGNE Neurogene Inc. Common Stock | $680.52M | — | $23.25 | ▼ 2.92% | $15.93$43.66 |
| PHAT Phathom Pharmaceuticals Inc. Common Stock | $678.76M | — | $6.92 | ▼ 7.73% | $6.52$18.31 |
| HELP Cybin Inc. Common Stock | $688.02M | — | $10.55 | ▼ 4.52% | $5.3$20.88 |
| EVO Evotec SE American Depositary Shares | $693.72M | — | $1.38 | ▼ 2.82% | $2.41$7.3 |
| FBIOP Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock | $662.39M | 0.58 | $16.67 | ▼ 1.30% | $1.88$4.53 |
| IRWD Ironwood Pharmaceuticals Inc. Class A Common Stock | $701.25M | 4.68 | $3.5 | ▼ 7.16% | $1.41$5.78 |
| IMMX Immix Biopharma Inc. Common Stock | $702.09M | — | $7.98 | ▼ 8.06% | $2.31$15.1 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- JP Morgan Initiates Coverage On Neurogene with Overweight Rating, Announces Price Target of $60benzinga · 10/8/2026
- JP Morgan Initiates Coverage On Neurogene with Overweight Rating, Announces Price Target of $60Benzinga · 10/8/2026
- Neurogene 13G Filing Shows Jennison Associates Reports 11.1% Stake In Co. As Of Sept. 30Benzinga · 10/6/2026
- Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo · 10/5/2026
Insider Activity
Insider Actions →- McMinn Rachel · September 22, 2026 · Option Exercise756 @ $25.32
- Cvijic Christine Mikail · July 7, 2026 · Sale4.2K @ $36.13
- Cvijic Christine Mikail · July 6, 2026 · Sale600 @ $36.02
- Cvijic Christine Mikail · July 2, 2026 · Sale1.5K @ $35.23
- Cvijic Christine Mikail · July 2, 2026 · Sale2.5K @ $34.58
- Cvijic Christine Mikail · July 1, 2026 · Sale739 @ $34.06
- Cvijic Christine Mikail · May 6, 2026 · Sale4.8K @ $30.07
- Shafer Christina · May 5, 2026 · Grant120.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 16.97M
- Total value held
- $342.01M
- Institutional holders
- 94
- Unknown1.72M
- Unknown1.46M
- Unknown1.42M
- Unknown1.36M
- Unknown1.27M
- Unknown1.01M
- Unknown991.7K
- Unknown782.8K
- Unknown718.4K
- Unknown681.3K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Neurogene Announces Inducement Grants Under Nasdaq Rules
Neurogene disclosed that it issued inducement grants in compliance with Nasdaq Listing Rule 5635(c)(4). This corporate action is typically used to attract or retain key personnel without requiring shareholder approval. The announcement provides context for the stock's current position near its support level, though no new financial results or clinical data were released in this update.
Neurogene Announces Inducement Grants Under Nasdaq Rules. Neurogene disclosed that it issued inducement grants in compliance with Nasdaq Listing Rule 5635(c)(4). This corporate action is typically used to attract or retain key personnel without requiring shareholder approval. The announcement provides context for the stock's current position near its support level, though no new financial results or clinical data were released in this update.